Certolizumab Pegol

Certolizumab is excreted into breastmilk in some, but not all, women in small amounts. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[1] Anti-TNF agents appear to reduce the levels of tumor necrosis factor and IP-10 in the milk of mothers with inflammatory bowel disease in the early postpartum period.[2] Polyethylene glycol is not excreted into breastmilk.[3] Numerous experts and professional guidelines have stated that the drug is a low risk to the nursing infant and acceptable to use during breastfeeding.[4-12]